Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash & Equivalents (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Cash & Equivalents data on record, last reported at $20.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 18.76% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, down 18.76%, while the annual FY2025 figure was $20.0 million, 18.76% down from the prior year.
  • Cash & Equivalents reached $20.0 million in Q4 2025 per ACRS's latest filing, down from $25.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $113.4 million in Q2 2021 and bottomed at $20.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $41.4 million, with a median of $36.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 248.14% in 2021, then tumbled 54.37% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $27.3 million in 2021, then soared by 65.55% to $45.3 million in 2022, then fell by 11.92% to $39.9 million in 2023, then crashed by 38.39% to $24.6 million in 2024, then decreased by 18.76% to $20.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $20.0 million in Q4 2025, $25.3 million in Q3 2025, and $25.4 million in Q2 2025.